Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AdvaMed Dx

This article was originally published in The Gray Sheet

Executive Summary

Diagnostics firms bioMerieux, Gen-Probe and Quidel recently joined AdvaMed's newly formed in-vitro-diagnostics-focused AdvaMed Dx division (1"The Gray Sheet" Dec. 21, 2009). Each of the companies had been in AdavMed at one time, but had let their memberships lapse

You may also be interested in...



AdvaMed Begets "AdvaMed Dx" For IVD-Focused Lobbying Effort

AdvaMed is forming an "association within an association" to focus exclusively on in vitro diagnostics, the group announced Dec. 17

QUOTED. 20 February 2020. Steven Raman.

Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.

Novartis Logs Into India With Digital Innovation Hub

Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.

Topics

UsernamePublicRestriction

Register

MT028513

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel